Appeals court validates Myriad's gene patents
13:14 EDT 16 Aug 2012 | BioCentury
The U.S. Court of Appeals for the Federal Circuit ruled again that composition and method claims in patents from Myriad Genetics Inc. (NASDAQ:MYGN) covering the breast cancer 1 early onset (BRCA1) and BRCA2 genes are valid under Section 101 of the Pa..
Original Article: Appeals court validates Myriad's gene patents
More From BioPortfolio on "Appeals court validates Myriad's gene patents"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
